DPDaniel A. Powell

Daniel A. Powell

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Daniel A. Powell has a total of 37 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Discovery of a Unique Set of Dog-Seroreactive Coccidioides Proteins Using Nucleic Acid Programmable Protein Array

    by Megan A. Koehler, Lusheng Song, Francisca J. Grill, Lisa F. Shubitz, Daniel A. Powell, John N. Galgiani, Marc J. Orbach, Edward J. Robb, Yunro Chung, Stacy A. Williams, et al.

    Valley Fever (VF), caused by fungi in the genus Coccidioides, is a prevalent disease in southwestern and western parts of the United States that affects both humans and animals, such as dogs. Although the immune responses to infection with Coccidioides spp. are not fully characterized, antibody-detection assays are used in conjunction with clinical presentation and radiologic findings to aid in the diagnosis of VF. These assays often use Complement Fixation (CF) and Tube Precipitin (TP) antigens as the main targets of IgG and IgM reactivity, respectively. Our group previously reported evidence of over 800 genes expressed at the protein level in C. posadasii. However, antibody reactivity to the majority of these proteins has never been explored. Using a new, high-throughput screening technology, the Nucleic Acid Programmable Protein Array (NAPPA), we screened serum specimens from dogs against 708 of these previously identified proteins for IgG reactivity. Serum from three separate groups of dogs was analyzed and revealed a small panel of proteins to be further characterized for immuno-reactivity. In addition to CF/CTS1 antigen, sera from most infected dogs showed antibody reactivity to endo-1,3-betaglucanase, peroxisomal matrix protein, and another novel reactive protein, CPSG_05795. These antigens may provide additional targets to aid in antibody-based diagnostics.


  • Open Access

    Evaluation of Pathogenesis and Immune Response to Coccidi-oides posadasii Infection in U.S. Feral Swine (Sus scrofa)

    by Rachel M. Maison, Peter Kessinger, Maggie R. Priore, Sushan Han, Daniel A Powell, Hilary Moale, Vienna R. Brown, Michael J. Bodenchuk, Richard A. Bowen, Angela M. Bosco-Lauth

    The dimorphic, soil-dwelling fungus Coccidioides is the causative agent of coccidioidomycosis and is a reemerging pathogen of human health concern. Despite increasing incidence and isolations of the organism outside of its theoretical environmental range, much of Coccidioides epidemiology, including complete host range, remains unknown. Feral swine (Sus scrofa) are an invasive species distributed throughout the United States that may play a role in fungal ecology due to their behavioral associations with soil. To address this, we evaluated seven feral swine for susceptibility to Coccidioides. After intranasal inoculation with 106.2 arthroconidia of C. posadasii, no pigs displayed signs of clinical disease, nor did any exhibit antibodies by AGID testing. Histopathologic evaluation did not reveal the presence granulomatous lesions, and fungal spherules or endospores were not observed in any of the tissue sections examined, although individuals had significant comorbidities, most notably Metastrongylus nematodes in the lungs. Despite the absence of lesions and organisms histologically, C. posadasii was isolated by culture from the lung and mediastinal lymph node of two pigs, indicating active infection. These results suggest that feral swine are mildly susceptible to acute Coccidioides infection and may aid in fungal dispersal due to the presence of spherules in tissues post-mortem.

  • Open Access

    Genetic and Other Determinants for the Severity of Coccidioidomycosis: A Clinician’s Perspective

    by John N. Galgiani, Amy P. Hsu, Daniel A. Powell, Jatin M. Vyas, Steven M. Holland

    The endemic fungal infection, coccidioidomycosis, occurs after inhalation of one or very few Coccidioides spp. spores. Infections produce diverse clinical manifestations, ranging from insignificant to extremely destructive, even fatal. Approaches to understanding this range of consequences have traditionally categorized patients into a small number of groups (asymptomatic, uncomplicated self-limited, fibro-cavitary, and extra-thoracic disseminated) and then looked for immunologic differences among them. Recently, variants within genes of innate pathways have been found to account, in part, for infections that result in disseminated disease. This discovery raises the very attractive theory that, in patients without severe immunosuppression, much of the disease spectrum can be accounted for by various combinations of such deleterious variants in innate pathways. In this review, we summarize what is known about genetic determinants that are responsible for the severity of coccidioidal infections and how complex innate genetic differences among different people might account for the spectrum of disease observed clinically.


  • Open Access

    Reactivation of Coccidioidomycosis in a Mouse Model of Asymptomatic Controlled Disease

    by Lisa F. Shubitz, Daniel A. Powell, Sharon M. Dial, Christine D. Butkiewicz, Hien T. Trinh, Amy P. Hsu, Adam Buntzman, Jeffrey A. Frelinger, John N. Galgiani

    The majority of human coccidioidomycosis infections are asymptomatic or self-limited but may have sequestered spherules in highly structured granulomas. Under immunosuppression, reactivation of fungal growth can result in severe disease. B6D2F1 mice asymptomatically infected with C. posadasii strain 1038 were immunosuppressed with dexamethasone (DXM) in drinking water. Treated mice died 16–25 days later, while untreated mice survived (p < 0.001). Flow cytometry of lung granulomas on days 5, 10, 15, and 20 of DXM treatment showed immune cell populations decreased 0.5–1 log compared with untreated mice though neutrophils and CD19+IgD−IgM− cells rebounded by day 20. Histopathology demonstrated loss of granuloma structure by day 5 and increasing spherules through day 20. On day 20, T-cells were nearly absent and disorganized pyogranulomatous lesions included sheets of plasma cells and innumerable spherules. Mice given DXM for 14 days then stopped (DXM stop) survived 6 weeks (9/10). Lung fungal burdens were significantly lower (p = 0.0447) than mice that continued treatment (DXM cont) but higher than untreated mice. Histopathologically, DXM stop mice did not redevelop controlled granulomas by sacrifice, though T-cells were densely scattered throughout the lesions. This demonstrates a mouse model suitable for further study to understand the immunologic components responsible for maintenance control of coccidioidomycosis.


  • Open Access

    Vaccines to Prevent Coccidioidomycosis: A Gene-Deletion Mutant of Coccidioides Posadasii as a Viable Candidate for Human Trials

    by John N. Galgiani, Lisa F. Shubitz, Marc J. Orbach, M. Alejandra Mandel, Daniel A. Powell, Bruce S. Klein, Edward J. Robb, Mana Ohkura, Devin J. Seka, Thomas M. Tomasiak, et al.

    Coccidioidomycosis is an endemic fungal infection that is reported in up to 20,000 persons per year and has an economic impact close to $1.5 billion. Natural infection virtually always confers protection from future exposure, and this suggests that a preventative vaccine strategy is likely to succeed. We here review progress toward that objective. There has been ongoing research to discover a coccidioidal vaccine over the past seven decades, including one phase III clinical trial, but for reasons of either efficacy or feasibility, a safe and effective vaccine has not yet been developed. This review first summarizes the past research to develop a coccidioidal vaccine. It then details the evidence that supports a live, gene-deletion vaccine candidate as suitable for further development as both a veterinary and a human clinical product. Finally, a plausible vaccine development plan is described which would be applicable to this vaccine candidate and also useful to other future candidates. The public health and economic impact of coccidioidomycosis fully justifies a public private partnership for vaccine development, and the development of a vaccine for this orphan disease will likely require some degree of public funding.